Tumor-derived transforming growth factors (TGF) concentration of 30 ng/ml being required to stimulate resorption in this system. The bone-resorting activity of TGF-a in fetal rat bones was inhibited by 10 ng/ml calcitonin but not by 5 X 10-7 M indomethacin. EGF at concentrations up to 300 ng/ml did not stimulate resorption of the limb bones at time periods up to 66 h. The results indicate that human TGF-a is a potent boneresorbing agent, and support the concept that this growth factor exhibits some effects distinct from those of EGF. TGF-a could play an etiologic role in the hypercalcemia of malignancy.
Introduction
The etiology of hypercalcemia in malignancy is uncertain. Prostaglandins (1), a parathyroid hormone (PTH)'-like protein (2) (3) (4) , and tumor-derived transforming growth factors (TGFs) are among the proposed mediators of the increased bone resorption and resultant hypercalcemia that typify some neoplasms. TGFs are polypeptide mitogens that are secreted by virus-transformed cells or neoplastic cells and confer the transformed phenotype, including anchorage-independent growth, on target cells (5, 6) . TGFs of the a-subtype (TGF-a) bind to the receptor for epi- 1 . Abbreviations used in this paper: cAMP, cyclic AMP; DME, Dulbecco's modified Eagle's medium; EGF, epidermal growth factor, HPLC, high performance liquid chromatography; PTH, parathyroid hormone; TGF(s), transforming growth factor(s); TGF-a, TGFs of the a-subtype. dermal growth factor (EGF) (7), a known stimulator of bone resorption in vitro (8, 9) . Hence, TGF-a could be a good candidate to mediate the hypercalcemic effect of neoplasms, and has been implicated in the bone-resorbing effects ofanimal tumor cells. The bone-resorbing substance secreted by rat Leydig tumor cells partially copurifies with a component(s) that has activity in assays of mitogenesis, anchorage-independent growth, and EGF receptor binding (10) ; and the bone-resorbing effect of medium conditioned by Leydig tumor cells is blocked by an antiserum to the EGF receptor (11) . The present studies were carried out to determine directly whether purified recombinant human TGF-a (12) is indeed a potent bone-resorbing substance.
Methods
Preparation of TGF-a. Human TGF-a was prepared by expression of a properly engineered cloned complementary DNA (cDNA) in Escherichia coli. The product was isolated as described (12) , and the preparations used herein were purified by high performance liquid chromatography (HPLC). The multiple peaks of recombinant TGF-a from HPLC were identical by amino acid analysis; with the predicted amino acid composition, but had different tryptic peptides; the HPLC peak with the greatest EGF-equivalent activity was used. The specific activity of this material varied from 10 to 44% of that of EGF in competition for EGF binding, possibly because ofvariable folding and disulfide bond formation (12) . TGF-a used in this work was assigned an EGF-equivalent activity (in nanograms/milliliter), based on competition for '25I-EGF binding to CCL64 mink lung cells (12) . When activities were expressed in this way, all TGF-a preparations used were equipotent in competing with 125[1 EGF for receptors in osteosarcoma cells.
Bone cultures. 45Ca-prelabeled 19-d fetal rat limb bones were cultured for 66 h in Dulbecco's modified Eagle's medium (DME) supplemented with 15% heat-inactivated (30 min, 560C) horse serum. Details of the method have been described previously (13, 14) . Resorption was quantified on the basis ofrelease of45Ca, confirmed by morphologic assessment of resorption at a magnification of 16. Neonatal (3-5 d) mouse calvaria were cultured in roller tubes containing 2 ml of DME, plus 15% heatinactivated horse serum. Details of the calvaria culture technique have been published previously (14) . Other materials used include bovine (b)PTH(1-34) (Bachem, Inc., Torrance, CA), EGF (Collaborative Research, Inc., Waltham, MA; and Bethesda Research Laboratories, Gaithersburg, MD), salmon calcitonin (a gift of Dr. J. Bastian, Armour Pharmaceutical Co., Tarrytown, NY) and indomethacin (Sigma Chemical Hepes, pH 7.4, and 1 mM isobutylmethylxanthine. Incubations were terminated by aspirating medium, washing the cells with 1 ml phosphatebuffered saline, and extracting cyclic AMP (cAMP) with three l-ml washes of absolute ethanol. Ethanol was evaporated in air and the extracts were dissolved in 1.0 ml 50 mM sodium acetate, pH 4.0, for cAMP assay ( 17) .
EGF binding assay. Confluent cultures of UMR-106 cells in 24-well plates were transferred to serum-free DME containing 0.1% bovine serum albumin. Cells were incubated at room temperature with -10,000 cpm of '25I-EGF (18) and unlabeled EGF or TGF-a. After 60 min, medium was removed and the cells were washed three times with 1 ml of phosphate-buffered saline. The cells were removed with 1 ml of0.5 N NaOH, and counted for '251I-radioactivity.
Statistics. Results were tested for significant differences by analysis of variance ( 19) .
Results TGF-a, at concentrations of 30-300 ng/ml, stimulated resorption of fetal rat limb bones (Fig. 1 ). Under these conditions (66-h incubation) EGF at similar concentrations had no bone-resorbing activity. This result was obtained using several preparations of EGF, whose biological activity was verified in assays of EGF receptor binding. The stimulatory effects ofTGF-a were unaffected by indomethacin (Table I) but were inhibited by salmon calcitonin (percent 45Ca released, mean±SE (n = 4): no treatment, 17.2±1.1; TGF-a, 300 ng/ml, 91.6±3.2; salmon calcitonin, 10 ng/ml, 14.8±0.4; TGF-a + salmon calcitonin, 16.4± 1.0). In contrast, neonatal mouse calvaria were maximally stimulated by 10 ng/ml TGF-a (Fig. 2 ) and the effects of TGFa, like those of EGF, were completely inhibited by 5 X 10-7 M indomethacin ( Table I) . As previously reported (8, 9) , indomethacin did not block the bone-resorbing effect of PTH in either assay (data not shown). As shown in Fig. 3 and neonatal mouse calvaria. In limb bones, TGF-a concentrations as low as 30 ng/ml stimulated resorption after 66 h. The calvaria were more sensitive to TGF-a, with maximal responses obtained with 10 ng/ml. The response of the two systems to TGF-a also differed, in that the effect in limb bones was insensitive to indomethacin, whereas that in the calvaria was completely blocked by the prostaglandin synthesis inhibitor. The two systems also differed in their relative responses to TGF-a and EGF. Neonatal mouse calvaria appeared to be equally sensitive to TGF-a and EGF. Previous studies with EGF in this same calvarial culture system indicated that 10 ng/ml was a maximally effective concentration of EGF (8) consistent with the effects of TGF-a seen here. Like the effect of TGF-a, the effect of EGF was inhibited by indomethacin in calvaria. In contrast, EGF failed to stimulate resorption in the rat limb bone cultures. The poor responses to EGF were not unexpected in view of the previous observations that long exposures (3-6 d) were required to produce resorption with EGF in fetal rat limb bones (9) . Similar disparities between the responses of fetal rat limb bones and neonatal mouse calvaria have been described previously, not only with respect to EGF (8, 9) , but with other factors that can produce release of prostaglandins. (21) . Certain of the data are consistent with the possibility that TGF-a stimulates resorption by interaction with a receptor for EGF. Since UMR-106 cells have osteoblast-like characteristics (16) and are known to possess surface receptors for EGF (20) , we used them to determine the relative affinities of EGF and recombinant human TGF-a for binding to the EGF receptor in rat bone cells. The finding that human TGF-a and EGF bind with similar affinity to the EGF receptor in osteosarcoma cells is consistent with results in fibroblast cell lines (12) and in the neonatal mouse calvaria. The observation that TGF-a was considerably more effective than EGF in stimulating bone resorption in fetal rat limb explants is more difficult to reconcile with the concept that they are acting through the same receptor. It has been suggested that in addition to the EGF receptor, TGF-a binds to a unique receptor in NRK and A43 1 cells (22) . Such a unique receptor may also be present in bone cells. However, in preliminary studies, specific '25I-TGF-a binding to UMR-106 cells can be displaced completely by EGF (Nissenson, R. A., and G. J. Strewler, unpublished observation). It is also possible that in contrast to its binding affinity in osteosarcoma cells, TGFa has a markedly higher affinity than EGF itself for a common receptor in fetal rat bone. However, the concentration of TGFa required to effect bone resorption is similar to the concentration necessary for binding to osteosarcoma cells. It remains possible that TGF-a and EGF bind similarly to the EGF receptor in rat limb bone cultures, but receptors occupied by TGF-a more effectively activate bone resorption.
Considerable evidence supports the proposal that in many instances, hypercalcemia in malignancy is mediated by a tumorderived protein that stimulates bone resorption via the PTH receptor, even though it is immunochemically distinct from PTH (2). This protein binds to the PTH receptor coupled to adenylate cyclase in renal plasma membranes (3, 4) and in osteosarcoma cells (16, 23 ). It appears that human TGF-a elicits increased bone resorption by a different pathway, since TGF-a does not stimulate cAMP production in osteosarcoma cells. It is ofinterest that the same renal carcinoma cell line from which messenger RNA (mRNA) for TGF-a was isolated (12) also secretes a PTHlike protein that binds to the PTH receptor and stimulates cAMP in osteosarcoma cells (16) .
TGFs have also been proposed as mediators ofhypercalcemia in malignancy, based on the following evidence: (a) rat Leydig tumor cells produce a bone-resorbing substance that copurifies with mitogenic activity, transforming activity (stimulation of anchorage-independent growth), and EGF receptor binding activity (10); (b) an antiserum to the EGF receptor blocks bone resorption by Leydig tumor cell medium (1 1); and (c) a hypercalcemic variant ofWalker 256 carcinosarcoma produces a boneresorbing substance with some similarities to TGF-a (e.g., acid stability, sensitivity to dithiothreitol), whereas a normocalcemic variant does not (24) . The present results indicating that recombinant human TGF-a is a potent bone-resorbing substance also support this view. The effects ofTGF-a are clearly distinguishable from those ofa PTH-like protein that is strongly associated with hypercalcemia in malignancy (2-4). Considerably more work will be required to define the frequency with which either of these two putative mediators causes hypercalcemia. In this regard, the availability of specific antisera (25) could permit the correlation ofblood levels ofTGF-a with humoral hypercalcemia in patients and animal subjects.
